Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and/or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Patients With Stable Ischemic Heart Disease and Preserved Left Ventricular Systolic Function

Slide: 25 of 29

Characteristics of Trials Evaluating the Addition of an ACEI or an ARB to Standard Medical Therapy (SMT) Versus SMT Alone Close to a Revascularization Procedure

This slide summarizes the seven trials that were evaluated in the Comparative Effectiveness Review (CER) to assess the benefits and harms of adding an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II-receptor blocker (ARB) to standard medical therapy, as opposed to standard medical therapy alone, in patients with stable ischemic heart disease who are in close proximity to a revascularization procedure. The patient population in these trials ranged from small (n = 91) to moderate (n = 2,553) in size. Typically, ACEIs were administered within a week after a revascularization procedure (as listed in the slide); in one trial, an ARB was given within 7 to 14 days before coronary stenting. In many of these trials, these treatment modalities were chosen to assess their impact on restenosis after these revascularization procedures. For detailed information on these trials, refer to the original comparative effectiveness review available at: http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=335.